We have observed
16 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Short interfering ribonucleic acid (siRNA)
SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY
STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES
INSULIN-LIKE GROWTH FACTOR MIMETICS FOR USE IN THERAPY
A PROCESS FOR PREPARING A COMPOSITION OF PEGYLATED PROTEINS
METHODS AND COMPOSITIONS USING FGF23 FUSION POLYPEPTIDES
IMPROVED FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
METHODS AND COMPOSITIONS USING KLOTHO VARIANT POLYPEPTIDES
COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
NOVEL ANDROGEN RECEPTOR MUTATION